SLC25A22 and cancer: Recently, glutamine has been exploited as a “metabolic checkpoint” with metabolic plasticity between cancer cells and effector T cells, and several studies have shown that the glutamine transporter inhibitor V‐9302 can effectively inhibit glutamine uptake.[35, 36] SLC25A22 has been previously implicated in tumorigenesis and immune modulation in colorectal cancer;[24, 25] however, its role in CSCC remained unexplored.